|
Report No. : |
306421 |
|
Report Date : |
04.02.2015 |
IDENTIFICATION DETAILS
|
Name : |
ACTAVIS PHARMA COMPANY |
|
|
|
|
Registered Office : |
6733 Mississauga Road, Ste 400 Mississauga, Ontario L5N 6J5 |
|
|
|
|
Country : |
Canada |
|
|
|
|
Date of Incorporation : |
27.12.2013 |
|
|
|
|
Legal Form : |
N.S. Unlimited Liability |
|
|
|
|
Line of Business : |
Manufactures and sells generic pharmaceuticals |
|
|
|
|
No. of Employees : |
100+ |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2014
|
Country Name |
Previous Rating (30.09.2014) |
Current Rating (31.12.2014) |
|
Canada |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
CANADA -
ECONOMIC OVERVIEW
As a high-tech industrial
society in the trillion-dollar class, Canada resembles the US in its
market-oriented economic system, pattern of production, and high living
standards. Since World War II, the impressive growth of the manufacturing,
mining, and service sectors has transformed the nation from a largely rural
economy into one primarily industrial and urban. The 1989 US-Canada Free Trade
Agreement (FTA) and the 1994 North American Free Trade Agreement (NAFTA) (which
includes Mexico) touched off a dramatic increase in trade and economic
integration with the US, its principal trading partner. Canada enjoys a
substantial trade surplus with the US, which absorbs about three-fourths of
Canadian merchandise exports each year. Canada is the US's largest foreign
supplier of energy, including oil, gas, uranium, and electric power. Given its
abundant natural resources, highly skilled labor force, and modern capital
plant, Canada enjoyed solid economic growth from 1993 through 2007. Buffeted by
the global economic crisis, the economy dropped into a sharp recession in the
final months of 2008, and Ottawa posted its first fiscal deficit in 2009 after
12 years of surplus. Canada's major banks, however, emerged from the financial
crisis of 2008-09 among the strongest in the world, owing to the financial
sector's tradition of conservative lending practices and strong capitalization.
Canada achieved marginal growth in 2010-13 and plans to balance the budget by
2015. In addition, the country's petroleum sector is rapidly expanding, because
Alberta's oil sands significantly boosted Canada's proven oil reserves. Canada
now ranks third in the world in proved oil reserves behind Saudi Arabia and
Venezuela
|
Source
: CIA |
Company name: ACTAVIS PHARMA COMPANY
Address: 6733 Mississauga Road, Ste 400
Mississauga, Ontario L5N 6J5 - Canada
Telephone: +1 905-814-1820
Fax: +1 905-814-8696
Website: www.actavis.ca
Corporate ID#: 32777762
State: Nova Scotia
Judicial form: N.S. Unlimited Liability
Date incorporated: 12-27-2013
Stock: -
Value: -
Name of
manager: Jean-Guy GOULET
History:
Business
issued from the merger of
- ACTAVIS
PHARMA COMPANY (ID# 3242221)
- ACTAVIS
PHARMA OTC COMPANY (ID# 3242228)
on
12-27-2013
Business:
ACTAVIS PHARMA COMPANY manufactures and sells generic pharmaceuticals in Canada.
The Company had the highest growth rate in prescriptions in the Canadian market and launched 10 products including Clopidogrel, Levonorgestrel, Latanoprost and Candesartan.
Additionally, the Company filed 20 applications during the year and launched a new sales organization in Quebec, which accounts for approximately 22% of the Canadian market.
Staff: 100+
Operations & branches:
At the
headquarters, we find a factory, warehouse and office.
Shareholders:
ACTAVIS INC.
400 Interspace Parkway
Parsippany, NJ 07054 – USA
Actavis, Inc., an integrated specialty pharmaceutical company, focuses on developing, manufacturing, marketing, and distributing generic, brand, and biosimilar products primarily in North America, Europe, Asia, the Middle East, and Africa. It develops and manufactures various molecules and dosage combinations, including urology and women’s health products; and biosimilars products in women’s health, oncology, and other therapeutic categories.
The company produces generic, brand, and over the counter pharmaceutical products in various formulations, including modified release, solid oral dosage, semi-solids, liquids, gels, transdermal products, and injectables.
It also develops and out-licenses generic pharmaceutical products to customers; and distributes products for third parties.
The ultimate parent company is:
ACTAVIS PLC
Grand Canal Square, Docklands
Dublin 2, Ireland
The Company is listed with the Nasdaq under symbol ACT.
Management:
Jean-Guy GOULET, President and Director.
He serves as the Chief Executive Officer and President of RATIOPHARM, INC.
Mr. Goulet has been the President of North America at Ratiopharm since 2006. He served as the President at Cobalt Pharmaceuticals Company, a subsidiary of Actavis Plc (formerly, Watson Pharmaceuticals, Inc.). Mr. Goulet joined Actavis Plc in 2011. He led Actavis' Canada and Latin America business.
He served as Chief Executive Officer and President of Ratiopharm Canada.
Mr. Goulet started his career in the quality control department at Technilab, which was later acquired by ratiopharm. He rapidly moved up within the organization, gaining increasing responsibilities in operations, sales, marketing and business development.
In 2002, he was appointed President of the Commercial division of Ratiopharm Canada. Mr. Goulet served as a Director of LYRtech Inc. from March 15, 2007 to January 23, 2008. He invested much time and energy in the development and representation of the Canadian Generic Pharmaceutical Association as the Chairman of the board of directors from 2002 to 2006 and was also part of the negotiation team during the federal patent law revisions from 1993 to 2006. Mr. Goulet graduated in Chemistry from Université de Montréal.
David Adam BUCHEN, Director and Secretary
R. Todd JOYCE, Director and Treasurer
Other Directors include Barbara PIMENTAL, Stephen KAUFHOLD, Bohdan WOLOSCUK,
Henry SOZIARSKI, Ali MOGHADDAM, and Kent R.J. Major.
Subsidiaries
And partnership: N/A
In Canada,
privately held corporations are not required to publish any financials.
On a direct
call, a financial assistant controlled the present report but deferred any
financials.
We sent a
fax but no answer received.
Consolidate
revenue 2012: USD 8,677,600,000=
Net
loss: USD 750,400,000=
Banks: Royal Bank of Canada
…
Legal filings & complaints:
As of today date, there is no legal filing pending with the Courts.
Secured debts summary: None
Haut du formulaire
Trade
references:
Date
reported: November 2014
High
credit: CAD 50,000+
Now owing: 0
Past due: 0
Last
purchase: October 2014
Line of
business: Office supply
Paying
status: On terms
Date
reported: November 2014
High
credit: CAD 180,000
Now owing: 0
Past due: 0
Last
purchase: October 2014
Line of
business: Payroll
Paying
status: As agreed
Date
reported: November 2014
High
credit: CAD 1,200
Now owing: 0
Past due: 0
Last
purchase: October 2014
Line of
business: Telecommunications
Paying
status: On terms
Domestic
credit history:
National
Credit Bureaus gave a satisfying credit rating.
Other
comments:
The Company
is developing a strong business.
The Company
is in good standing.
This means
that all local and federal taxes were paid on due date.
Last report
was filed on May 8, 2014.
The risk is
low.
Our
opinion:
A business
connection may be conducted.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.61.74 |
|
|
1 |
Rs.92.71 |
|
Euro |
1 |
Rs.69.94 |
INFORMATION DETAILS
|
Report Prepared
by : |
TPT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall
operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment record
(10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.